The Orbital Research Economy: Why Standards Will Decide the Winners

Jan de Vries · 2026-10-05

I watched SpaceX go public with the same mixed feeling I suspect a lot of people in this industry did: relief, mostly. The largest listing in history just told the market, in the blunt language it actually understands, that space is a real asset class and not a rich man's hobby. Good. This was needed. But the IPO only validated the launch business. The part of the orbital economy focused on real pharmaceutical research in microgravity is still not an industry. It's a scrapbook of brilliant one-off experiments. And what stands between those two states isn't another rocket. It's something far less glamorous: standards. ### The science is no longer the question For those asking "is space-based pharmaceutical research even real?" That question has been out of the way for a while now. - MSD grew crystals of its blockbuster cancer drugs on the International Space Station and ended up with new, more uniform crystal forms. That kind of result matters because better crystals can help extend patent protection on a medicine that brings in tens of billions of dollars a year. - Brazilian geneticist and developmental biologist Alysson Muotri has been sending tiny, lab-grown models of human brain tissue to space. In microgravity, these "brain organoids" aged at the molecular level much faster – by about a decade – than they would on Earth. That finding has now helped seed the first clinical trial for a neurological condition built on discoveries made in space. - Arun Sharma flew human heart cells derived from stem cells and watched them self-organize into more mature, better-structured heart tissue in orbit than in any dish on the ground. - Meenal Datta from the University of Notre Dame grew mini-tumors alongside immune cells and found they formed more consistent, more realistic cancers in space, with structures that actually mirror the disease in patients. - Catriona Jamieson, UC San Diego Sanford Stem Cell Institute Director, has taken this furthest. Her team saw cancer stem cells in space renew themselves and switch on a key enzyme, ADAR1, far faster than they ever do on Earth. That "fast-forwarded" data now underpins a Phase 1 clinical trial running back on the ground. This isn't speculative. Evidence shows microgravity gives you biology you cannot get on Earth. And since most drug candidates still die in the clinic, very often because the early models quietly lied to us, better models aren't a nice-to-have, they're the whole game. Every one of those failures is years of someone's working life and a few hundred million dollars gone into failed trials. If orbit can move that number even a little, the prize is enormous. ### Why pharma still isn't buying So here's the question: if the science is this good, why isn't every serious pharma already up there? The uncomfortable answer is that the space community, collectively, has made this work almost impossible to buy. A result you can't reproduce, validate, and compare isn't an asset to a regulated company; it's just a nice story. That's wonderful for a proof of concept, but completely useless the moment a quality director of a biotech company has to put their name on it. Pharma buys when the hardware is validated, the procedure repeats across operators, and the numbers line up against other numbers. In orbit, we've been so busy proving we can run the experiment that we forgot to make anyone able to trust it. ### Space does not need its own rulebook Now the part where I think this industry is about to make a genuinely expensive mistake. When you're doing something that feels this new, there's an almost irresistible pull to invent new rules for it. A shiny "space-grade" quality framework, a certification with the word "orbital" stamped on it. I understand the instinct, and I think it's wrong from the point of commercialization, because the entire value of a microgravity result is that you can hold it up against what we already know. Pharma has spent decades and, conservatively, hundreds of billions of dollars building a regulatory and quality system that the FDA and EMA trust. That system is the asset. Not the rocket. If the orbital research community tries to build a parallel universe of standards, it will fail. Not because the standards are bad, but because no pharma quality director will stake their career on a framework that hasn't been through the wringer. They need to see their own language, their own validation protocols, their own audit trails. The moment you ask them to learn a new religion, you've lost them. The winning move is boring: adopt existing pharma standards wholesale. Use the same equipment qualification, the same documentation practices, the same chain-of-custody rules. Then, and only then, will microgravity research become an asset class instead of a curiosity. SpaceX proved there's money in orbit. The next trillion will go to whoever makes orbit boring enough for pharma to buy.